Nurix Therapeutics Strengthens Board with Former Pfizer and Seagen Executive Roger Dansey
核心洞察
Nurix Therapeutics appointed Roger Dansey, M.D., former Chief Development Officer and Chief Oncology Officer of Pfizer Oncology, to its board of directors.
Dr. Dansey brings over two decades of leadership experience in drug development and commercialization, having contributed to multiple breakthrough cancer (搜索) medicine approvals.
The appointment comes as Nurix accelerates pivotal trials for its lead BTK (搜索) degrader bexobrutideg (搜索) in chronic lymphocytic leukemia (搜索).
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced the appointment of Roger Dansey, M.D., to its board of directors on November 10, 2025. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., brings over two decades of leadership experience in drug development and commercialization to the clinical-stage biopharmaceutical company.
Strategic Leadership Addition
"Roger is one of the leading experts in oncology research, and a key contributor to the clinical development and subsequent approvals of multiple breakthrough cancer (搜索) medicines," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "I am honored to welcome Roger to our board of directors, and I look forward to his guidance and leadership as we accelerate the implementation of pivotal trials for our lead asset, bexobrutideg (搜索), in chronic lymphocytic leukemia (搜索), and explore the use of protein degradation in autoimmune diseases (搜索)."
Dr. Dansey's appointment comes at a pivotal time for Nurix as the company advances its targeted protein degradation platform. The new board member expressed enthusiasm about joining the company, stating, "Nurix is pioneering a transformative approach to drug discovery through targeted protein degradation, with the potential to fundamentally change how we treat not only cancer (搜索) but also autoimmune disease."
Extensive Industry Experience
Dr. Dansey's career spans multiple major pharmaceutical companies and breakthrough drug developments. He served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology from January 2024 until his retirement in March 2025. Prior to that, he held the position of President, Research and Development of Seagen from November 2022 until Pfizer's acquisition of Seagen in December 2023.
His tenure at Seagen was particularly relevant to Nurix's mission, as Dr. Dansey noted: "I learned of Nurix's breakthrough science of targeted protein degradation during my tenure at Seagen as we sought to create the next generation of antibody drug conjugates, which became our degrader antibody conjugate, or DAC program, now a significant drug discovery initiative in the field."
Earlier in his career, Dr. Dansey held senior clinical development leadership positions including Therapeutic Area Head for Late-Stage Oncology at Merck & Co. (搜索), Inc., where he was responsible for registration efforts for Keytruda (pembrolizumab) across multiple tumor types. He also served as Vice President of Oncology Clinical Research at Gilead Sciences and as Global Development Lead for Xgeva (denosumab) at Amgen.
Nurix's Protein Degradation Platform
Nurix Therapeutics focuses on targeted protein degradation medicines, which the company describes as "the next frontier in innovative drug design aimed at improving treatment options for patients with cancer (搜索) and autoimmune diseases (搜索)." The company's clinical-stage pipeline includes degraders of Bruton's tyrosine kinase (搜索) (BTK (搜索)), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B (搜索)), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells.
The company is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline includes a preclinical stage degrader of STAT6, a clinical stage degrader of IRAK4 (搜索) in collaboration with Gilead, and multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc.
AI-Integrated Discovery Platform
Nurix has built what it describes as a "fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise." This platform represents the company's approach to translating the science of targeted protein degradation into clinical advancements, with the goal of establishing degrader-based treatments at the forefront of patient care.
Dr. Dansey currently serves on the boards of directors of Bicycle Therapeutics plc, Inovio Pharmaceuticals, Inc., MycRX Pharma, Ottimo Pharma Ltd and Shasqi Inc. He holds an M.D. from the University of Witwatersrand, Johannesburg, South Africa, and was previously an associate professor of hematology and oncology at the Karmanos Cancer (搜索) Institute in Detroit before joining the pharmaceutical industry.